CytomX Therapeutics, Inc.
CTMX
Rank in Stocks
#12900
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company... CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Share Price
$1.98
Last synced: 2026-11-09
Market Cap
$431.44M
Change (1 day)
-9.59%
Change (1 year)
-51.71%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CytomX Therapeutics, Inc. (CTMX)
Category
Healthcare
EPS for CytomX Therapeutics, Inc. (CTMX)
EPS as of September 2026 TTM: $-0.45
According to CytomX Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.45. At the end of 2025 the company had an EPS of $-0.15, a decrease compared to its 2024 EPS of $0.38.
EPS history for CytomX Therapeutics, Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.45 | 200.00% |
| 2025 | $-0.15 | -139.47% |
| 2024 | $0.38 | -5,035.06% |
| 2023 | $-0.01 | -99.48% |
| 2022 | $-1.48 | 17.46% |
| 2021 | $-1.26 | 77.46% |
| 2020 | $-0.71 | -68.58% |
| 2019 | $-2.26 | 11.33% |
| 2018 | $-2.03 | 75.00% |
| 2017 | $-1.16 | -28.83% |
| 2016 | $-1.63 | 63.00% |
| 2015 | $-1.00 | 14.94% |
| 2014 | $-0.87 | -94.32% |
| 2013 | $-15.32 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,580.00% |
US
|
|
| $-7.07 | 1,471.11% |
US
|
|
| $-5.29 | 1,075.56% |
AU
|
|
| $12.88 | -2,962.24% |
BE
|
|
| $21.56 | -4,891.11% |
NL
|
Questions about CytomX Therapeutics, Inc.'s earnings per share (EPS)
What is CytomX Therapeutics, Inc.'s earnings per share (EPS)?
CytomX Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.45, as of Sep 2026.
What was CytomX Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, CytomX Therapeutics, Inc.'s earnings per share (EPS) was $-0.15, compared with $0.38 in 2024.
How has CytomX Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, CytomX Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($0.38) and lowest in 2022 ($-1.48).
How does CytomX Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
CytomX Therapeutics, Inc.'s earnings per share (EPS) ($-0.45) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.